Zobrazeno 1 - 10
of 2 202
pro vyhledávání: ''
Autor:
Hailing Cheng, Pixu Liu, Li Li, Zhiwei Tao, Zundong Liu, Yichao Liu, Xiaolin Sang, Chunhua Rui
Publikováno v:
Cancer Letters. 518:82-93
Despite HER2-targeted cancer treatments have provided considerable clinical benefits, resistance to HER2-targeted agents will inevitably develop. Targeting non-oncogene vulnerabilities including endoplasmic reticulum (EnR) stress has emerged as an at
Publikováno v:
Cancer Biomarkers. 32:207-219
BACKGROUND: FAS can serve as both an oncogene and a suppresser in different malignancies, and the prognostic value of FAS remains controversial. METHODS: The Oncomine database, KM-Plotter and bc-GenExMiner platform were adopted to analyze the prognos
Autor:
Alexander Stein, Maurice Michel, Jens U. Marquardt, Helge Schroeder, Oliver Waidmann, Marcus-Alexander Woerns, Arndt Weinmann, Markus Moehler, Martin Maenz, Joseph Tintelnot, Friedrich Foerster, Joerg Trojan
Publikováno v:
Future Oncology. 17:3309-3319
Aim: To determine a recommended Phase II dose of the oral fluoropyrimidine trifluridine/tipiracil (FTD/TPI) combined with the multi-kinase inhibitor regorafenib (REG) in refractory metastatic colorectal cancer patients. Materials & methods: A convent
Publikováno v:
Gynecologic Oncology. 162:482-495
Inhibitors of poly(ADP-ribose) polymerase (PARP) and angiogenesis have demonstrated single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to establish whether combination therapy can augment the response seen with PAR
Autor:
Eric S. Geanes, Sean M. Holloran, Anuradha Roy, Olivia K. Provance, Sumedha Gunewardena, Christy R. Hagan, Scott Weir, Asona Lui, Joan Lewis-Wambi
Publikováno v:
Cancer Lett
Overexpression of interferon induced transmembrane protein-1 (IFITM1) enhances tumor progression in multiple cancers, but its role in triple-negative breast cancer (TNBC) is unknown. Here, we explore the functional significance and regulation of IFIT
Autor:
Mario M. Leitao, Nadeem R. Abu-Rustum, Anoushka M. Afonso, William A. Zammarrelli, Jennifer J. Mueller, Amelia Chan, Vance Broach, Oliver Zivanovic, Yukio Sonoda
Publikováno v:
Gynecol Oncol
Objective To describe the incidence of adverse reactions to indocyanine green (ICG) administered during sentinel lymph node (SLN) biopsy for endometrial cancer, and to propose an ICG management algorithm for these patients. Methods All patients who u
Autor:
Silvia Olivari, Gary Binder, Erminio Bonizzoni, Eric Roeland, Rudolph M. Navari, Rebecca Clark-Snow
Publikováno v:
Future Oncology. 17:3027-3035
Aim: In the absence of comparative studies, guidelines consider neurokinin 1 receptor antagonists (RAs) as interchangeable. We evaluated the pooled efficacy from three cisplatin registration trials, each with arms containing netupitant/palonosetron (
Autor:
Alison Conlin, Thomas Boulet, Georg Kunz, J.C. Alcedo, Andrea Fontana, Irene Wapnir, Norman Wolmark, Xavier Pivot, Max S. Mano, Adam Brufsky, S. Loibl, D. Tesarowski, Chunyan Song, Bella Kaufman, Youngsen Yang, Melanie Smitt, Mahasti Saghatchian, Martina Zimovjanova, Michael Untch, G. von Minckwitz, Jonathan Polikoff, Charles E. Geyer, S. Kuemmel, H. Liu, Eleftherios P. Mamounas, John Hackmann, Lisa H. Lam, C.-S. Huang, T. Kuehn, Michael P. DiGiovanna
Publikováno v:
Annals of Oncology. 32:1005-1014
Background In the KATHERINE study (NCT01772472), patients with residual invasive early breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus human epidermal growth factor receptor 2 (HER2)-targeted therapy had a 50% reduction in risk of recu
Autor:
T. García, Juan de la Cámara Gómez, Alberto Carmona-Bayonas, Marta Covela Rúa, Francisca Vázquez Rivera, Paula Jiménez-Fonseca, Manuel Cánovas, Ana Montes, Carmen Carriles Fernández, Paula Gonzalez Villarroel, Nieves Martinez Lago, Antía Cousillas Castiñeiras, J. Méndez
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports
Scientific Reports
Trifluridine/tipiracil increases overall survival (OS) in patients with refractory, metastatic colorectal cancer (mCRC). A post hoc exploratory analysis of the RECOURSE randomized clinical trial (RCT) established two categories, a good prognosis corr
Autor:
Julie A. Douglas, Daniel L. Hertz, N. Lynn Henry, Zeruesenay Desta, Daniel F. Hayes, Todd C. Skaar, James M. Rae, Christina L. Gersch, Vered Stearns, Ana Maria Storniolo, Kelley M. Kidwell
Publikováno v:
Pharmacogenet Genomics
OBJECTIVE: Letrozole is a non-steroidal aromatase inhibitor (AI) used to treat hormone receptor positive (HR+) breast cancer. Variability in letrozole efficacy and toxicity may be partially attributable to variable systemic drug exposure, which may b